Mirum Pharmaceuticals
MIRM· Manufacturing· Fiscal year ends in December
Christopher Peetz is the CEO of Mirum Pharmaceuticals and was paid $10.4M in FY2025 (Dec), up 58%.
Executives4
See all- 1Christopher PeetzChief Executive OfficerFY2025
- 2Peter RadovichPresident and Chief Operating OfficerFY2025
- 3Eric Bjerkholt, M.B.A.Chief Financial OfficerFY2025
- 4Joanne Quan, M.D.Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMirum Pharmaceuticals paid its 4 named executives $20.9M in total in FY2025 (Dec). CEO Christopher Peetz was paid $10.4M of that.
| Name | |||
|---|---|---|---|
| Christopher PeetzChief Executive Officer | |||
| Peter RadovichPresident and Chief Operating Officer | |||
| Eric Bjerkholt, M.B.A.Chief Financial Officer | |||
| Joanne Quan, M.D.Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers21
See allThe FY2025 (Dec) proxy of Mirum Pharmaceuticals names 21 peer companies for pay. Among Mirum Pharmaceuticals and these peers, CEO pay was 5th highest of 7 and total shareholder return was the highest of 7.
5th highest of 7in Mirum Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
1st highest of 7in Mirum Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board3
See all- Laura BregeDirector · 4 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
- Laurent FischerDirector · 4 yr on the boardIndependentCompensation—Paid as an executive
- William C. FaireyDirector · 2 yr on the boardIndependentAudit, Compensation—Paid as an executive
The board of the latest proxy (FY2023).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Feb 25, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 14, 2025 | FY2024 |
| Annual report | 10-K | Feb 26, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 23, 2024 | FY2023 |
| Annual report | 10-K | Mar 15, 2024 | FY2023 |
